{"id":"opioid-dose-escalation","safety":{"commonSideEffects":[{"rate":null,"effect":"Respiratory depression"},{"rate":null,"effect":"Constipation"},{"rate":null,"effect":"Sedation"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Overdose risk"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This is a dosing strategy rather than a novel drug entity. It involves titrating opioid doses upward over time to overcome tolerance or achieve adequate pain control in opioid-tolerant patients. The mechanism relies on the existing pharmacology of opioid receptor agonism, with escalation used to maintain therapeutic effect as patients develop tolerance to the drug.","oneSentence":"Opioid dose escalation is a clinical practice of incrementally increasing opioid medication doses to maintain analgesic efficacy in patients with chronic pain.","_ai_confidence":"low"},"_scrapedAt":"2026-03-27T23:58:36.323Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic pain management in opioid-tolerant patients"},{"name":"Cancer pain"},{"name":"Severe chronic non-cancer pain"}]},"trialDetails":[{"nctId":"NCT06441604","phase":"PHASE2","title":"Extended-release Buprenorphine as a Novel Low-dose Induction Strategy","status":"RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2025-10-27","conditions":"Opioid Use Disorder","enrollment":30},{"nctId":"NCT07264270","phase":"PHASE1","title":"Study to Evaluate Safety of C-1101 Versus Sterile Saline in Adults With Chronic Painful Lumbosacral Radiculopathy","status":"RECRUITING","sponsor":"Consano Bio","startDate":"2025-12-03","conditions":"Lumbosacral Radicular Pain, Sciatic Radiculopathy, Sciatic Leg Pain","enrollment":24},{"nctId":"NCT06576830","phase":"PHASE4","title":"Optimization of Pediatric Tonsillectomy to IMprove AnaLgesia","status":"RECRUITING","sponsor":"Duke University","startDate":"2024-11-21","conditions":"Pain, Postoperative, Tonsillar Hypertrophy, Tonsillitis","enrollment":440},{"nctId":"NCT05825560","phase":"PHASE4","title":"Opioid-free Analgesia in Intensive Care Unit","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire de Nīmes","startDate":"2023-05-15","conditions":"Intubation","enrollment":50},{"nctId":"NCT03747341","phase":"PHASE1","title":"Buprenorphine-Fentanyl Interaction Study","status":"COMPLETED","sponsor":"Indivior Inc.","startDate":"2018-03-22","conditions":"Healthy, Opioid Use","enrollment":22},{"nctId":"NCT06538558","phase":"PHASE1","title":"Study to Assess the Use of Tezampanel for Opioid Withdrawal Syndrome in Treatment-Seeking Patients With Opioid Use Disorder","status":"RECRUITING","sponsor":"Proniras Corporation","startDate":"2024-10-16","conditions":"Opioid Use Disorder","enrollment":40},{"nctId":"NCT02454712","phase":"PHASE1","title":"Study of PF614 Compared to OxyContin® in Healthy Volunteers (PF614-101)","status":"COMPLETED","sponsor":"Ensysce Biosciences","startDate":"2016-11-16","conditions":"Healthy","enrollment":64},{"nctId":"NCT05043766","phase":"PHASE1","title":"Evaluation of Oral PF614 Relative to OxyContin (PF614-102)","status":"COMPLETED","sponsor":"Ensysce Biosciences","startDate":"2021-09-08","conditions":"Healthy Volunteers","enrollment":84},{"nctId":"NCT05644587","phase":"PHASE4","title":"Novel Induction to Buprenorphine/Naloxone","status":"TERMINATED","sponsor":"Bicycle Health","startDate":"2023-02-06","conditions":"Opioid Use Disorder, Opioid Use, Opioid Abuse","enrollment":33},{"nctId":"NCT03933397","phase":"PHASE3","title":"Comparing Individualized vs. Weight Based Protocols to Treat Vaso-Occlusive Episodes in Sickle Cell Disease","status":"TERMINATED","sponsor":"Duke University","startDate":"2019-08-13","conditions":"Sickle Cell Disease","enrollment":328},{"nctId":"NCT05411861","phase":"PHASE2","title":"Post-Operative Pain and Opioid Reduction Trial After Bunionectomy","status":"COMPLETED","sponsor":"Cali Pharmaceuticals LLC","startDate":"2022-06-14","conditions":"Hallux Valgus and Bunion","enrollment":73},{"nctId":"NCT03945084","phase":"PHASE2","title":"Maintenance With Niraparib In Patients With Advanced Urothelial Cancer After 1st-line Platinum-based Chemotherapy","status":"COMPLETED","sponsor":"University of Turin, Italy","startDate":"2019-08-27","conditions":"Urothelial Carcinoma","enrollment":58},{"nctId":"NCT00838981","phase":"PHASE1, PHASE2","title":"Pharmacotherapy & CM for Opioid and Cocaine Dependence","status":"COMPLETED","sponsor":"Yale University","startDate":"2008-05","conditions":"Cocaine Dependence","enrollment":91},{"nctId":"NCT03024515","phase":"NA","title":"Opioids Titration Study in Advanced Cancer Patients in Hong Kong","status":"COMPLETED","sponsor":"Chinese University of Hong Kong","startDate":"2018-08-23","conditions":"Pain Control","enrollment":2},{"nctId":"NCT04301336","phase":"PHASE2, PHASE3","title":"Different Treatment Modalities in the Management of the Painful Crisis in Pediatric Sickle- Cell Anemia","status":"COMPLETED","sponsor":"Beni-Suef University","startDate":"2019-11-01","conditions":"Vaso-occlusive Crisis, Sickle Cell Disease, Sickle Cell Anemia in Children","enrollment":350},{"nctId":"NCT01333540","phase":"PHASE2","title":"A Study to Assess the Safety, Tolerability and Clinical Activity of TD-1211 in Patients With Opioid-Induced Constipation","status":"COMPLETED","sponsor":"Theravance Biopharma","startDate":"2011-05","conditions":"Opioid-induced Constipation (OIC)","enrollment":69},{"nctId":"NCT03123861","phase":"PHASE4","title":"Gabapentin for Postop Pain After SSLF","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2017-06-01","conditions":"Pelvic Organ Prolapse","enrollment":45},{"nctId":"NCT04265456","phase":"PHASE1","title":"A Phase 1 Study to Evaluate Pregabalin and Acetaminophen in Healthy Volunteers","status":"COMPLETED","sponsor":"Nevakar, Inc.","startDate":"2020-01-14","conditions":"Postoperative Pain","enrollment":63},{"nctId":"NCT04175743","phase":"PHASE1","title":"Double-blind, Placebo-control, Study to Evaluate the Safety and Pharmacokinetics of CT-044 HCl, in Healthy Volunteers","status":"UNKNOWN","sponsor":"Lotus Clinical Research, LLC","startDate":"2019-12-04","conditions":"Acute Pain, Pain, Acute, Surgery","enrollment":21},{"nctId":"NCT03766269","phase":"PHASE2","title":"Dronabinol Opioid Sparing Evaluation (DOSE) Trial","status":"UNKNOWN","sponsor":"Daisy Pharma Opioid Venture, LLC","startDate":"2018-12-01","conditions":"Chronic Pain","enrollment":280},{"nctId":"NCT01708707","phase":"PHASE2","title":"Comparison of Buprenorphine to Morphine in Treatment of Neonatal Abstinence Syndrome (NAS)","status":"COMPLETED","sponsor":"Pediatrix","startDate":"2012-12","conditions":"Neonatal Abstinence Syndrome, Neonatal Withdrawal Syndrome","enrollment":29},{"nctId":"NCT00706576","phase":"PHASE1","title":"Treatment of Unresectable Hepatocellular Cancer With Opioid Growth Factor","status":"COMPLETED","sponsor":"University of Missouri-Columbia","startDate":"2008-06","conditions":"Hepatocellular Cancer","enrollment":14},{"nctId":"NCT00857883","phase":"PHASE1","title":"A First-Time-In-Human Study in Healthy Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-11-17","conditions":"Obesity","enrollment":56},{"nctId":"NCT01875848","phase":"PHASE4","title":"Buprenorphine vs. Opioid Dose Escalation Among Patients With Chronic Pain","status":"TERMINATED","sponsor":"VA Office of Research and Development","startDate":"2013-12","conditions":"Pain","enrollment":7},{"nctId":"NCT00465647","phase":"PHASE4","title":"An Open-label Study of Hydromorphone Oral Solution in Subjects Aged 28 Days to 16 Years for Postoperative Pain","status":"COMPLETED","sponsor":"Purdue Pharma LP","startDate":"2007-04","conditions":"Postoperative Pain","enrollment":116},{"nctId":"NCT00600119","phase":"PHASE2","title":"A Phase 2, Double-Blind, Multiple-Dose Escalation Study to Evaluate NKTR-118 (Oral PEG-Naloxol) in Patients With Opioid-Induced Constipation (OIC)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2007-12","conditions":"Opioid Induced Constipation (OIC)","enrollment":207},{"nctId":"NCT02084355","phase":"PHASE3","title":"Study of Opioid Rotation Versus Opioid Escalation in Patients With Moderate to Severe Cancer Pain","status":"UNKNOWN","sponsor":"Gyeongsang National University Hospital","startDate":"2014-04","conditions":"Cancer, Pain","enrollment":136},{"nctId":"NCT00644787","phase":"PHASE2, PHASE3","title":"A Dose-Finding Study of Fentanyl (JNS020 QD) 1-Day Transdermal Patch in Participants With Cancer Pain","status":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","startDate":"2007-12","conditions":"Pain, Cancer","enrollment":156},{"nctId":"NCT00641667","phase":"PHASE3","title":"An Efficacy and Safety Study of Fentanyl (JNS020QD) in Participants With Cancer Pain","status":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","startDate":"2008-01","conditions":"Pain, Cancer","enrollment":66},{"nctId":"NCT01151098","phase":"PHASE3","title":"Safety of Buprenorphine Transdermal Systems in Subjects With Chronic Nonmalignant Pain - a 28-week Extension Study","status":"COMPLETED","sponsor":"Purdue Pharma LP","startDate":"2001-04","conditions":"Chronic Nonmalignant Pain","enrollment":189},{"nctId":"NCT01207206","phase":"NA","title":"Oral Ketamine as an Adjuvant to Opioids for Pain Treatment in Cancer Patients","status":"UNKNOWN","sponsor":"Tel-Aviv Sourasky Medical Center","startDate":"2010-10","conditions":"Cancer, Pain, Tolerance","enrollment":50},{"nctId":"NCT00255333","phase":"PHASE1","title":"INNO-105 in Patients With Solid Tumors","status":"TERMINATED","sponsor":"Innovive Pharmaceuticals","startDate":"2005-11","conditions":"Tumors","enrollment":24}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":66,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["No other names"],"phase":"marketed","status":"active","brandName":"opioid dose escalation","genericName":"opioid dose escalation","companyName":"VA Office of Research and Development","companyId":"va-office-of-research-and-development","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Opioid dose escalation is a clinical practice of incrementally increasing opioid medication doses to maintain analgesic efficacy in patients with chronic pain. Used for Chronic pain management in opioid-tolerant patients, Cancer pain, Severe chronic non-cancer pain.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}